Dopamine-serotonin system stabilizer. Exhibits partial agonist activity at dopamine D2-receptors and serotonin 5-HT1A-receptors and antagonist activity at 5-HT2A-receptors. Prepn: Y. Oshiro et al., EP 367141; eidem, US 5006528 (1990, 1991 both to Otsuka); and pharmacology: Y. Oshiro et al., J. Med. Chem. 41, 658 (1998). Description of action on dopamine receptors: S. M. Stahl, J. Clin. Psychiatry 62, 841, 923 (2001); on serotonin receptors: S. Jordan et al., Eur. J. Pharmacol. 441, 137 (2002). Clinical trial in schizophrenia: J. M. Kane et al., J. Clin. Psychiatry 63, 763 (2002). Review of pharmacology: J. K. McGavin, K. L. Goa, CNS Drugs 16, 779-786 (2002); and clinical experience: P. E. Keck Jr., S. L. McElroy, Expert Opin. Invest. Drugs 12, 655-662 (2003).
Antipsychotic.
Antipsychotic; Dopamine-Serotonin System Stabilizer